DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on January 12, 2007; DOI: 10.1124/dmd.106.013110

0090-9556/07/3504-525-532$20.00
DMD 35:525-532, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.013110v1
35/4/525    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beconi, M. G.
Right arrow Articles by Vincent, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beconi, M. G.
Right arrow Articles by Vincent, S. H.

Disposition of the Dipeptidyl Peptidase 4 Inhibitor Sitagliptin in Rats and Dogs

Maria G. Beconi, James R. Reed, Yohannes Teffera, Yuan-Qing Xia, Christopher J. Kochansky, David Q. Liu, Shiyao Xu, Charles S. Elmore, Suzanne Ciccotto, Donald F. Hora, Ralph A. Stearns, and Stella H. Vincent

Departments of Drug Metabolism (M.G.B., J.R.R., Y.T., Y.-Q.X., C.J.K., D.Q.L., S.X., C.S.E., S.C., R.A.S., S.H.V.) and Comparative Medicine (D.F.H.), Merck Research Laboratories, Rahway, New Jersey

The pharmacokinetics, metabolism, and excretion of sitagliptin [MK-0431; (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine], a potent dipeptidyl peptidase 4 inhibitor, were evaluated in male Sprague-Dawley rats and beagle dogs. The plasma clearance and volume of distribution of sitagliptin were higher in rats (40–48 ml/min/kg, 7–9 l/kg) than in dogs (~9 ml/min/kg, ~3 l/kg), and its half-life was shorter in rats, ~2 h compared with ~4 h in dogs. Sitagliptin was absorbed rapidly after oral administration of a solution of the phosphate salt. The absolute oral bioavailability was high, and the pharmacokinetics were fairly dose-proportional. After administration of [14C]sitagliptin, parent drug was the major radioactive component in rat and dog plasma, urine, bile, and feces. Sitagliptin was eliminated primarily by renal excretion of parent drug; biliary excretion was an important pathway in rats, whereas metabolism was minimal in both species in vitro and in vivo. Approximately 10 to 16% of the radiolabeled dose was recovered in the rat and dog excreta as phase I and II metabolites, which were formed by N-sulfation, N-carbamoyl glucuronidation, hydroxylation of the triazolopiperazine ring, and oxidative desaturation of the piperazine ring followed by cyclization via the primary amine. The renal clearance of unbound drug in rats, 32 to 39 ml/min/kg, far exceeded the glomerular filtration rate, indicative of active renal elimination of parent drug.

Address correspondence to: Dr. Stella Vincent, RY 80-141, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065. E-mail: stella_vincent{at}merck.com




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
S. H. Vincent, J. R. Reed, A. J. Bergman, C. S. Elmore, B. Zhu, S. Xu, D. Ebel, P. Larson, W. Zeng, L. Chen, et al.
Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans
Drug Metab. Dispos., April 1, 2007; 35(4): 533 - 538.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.